Wang Yuli, Decker Stuart J, Sebolt-Leopold Judith
Cancer Molecular Sciences Department, Pfizer Global Research and Development, Ann Arbor Laboratories, Ann Arbor, Michiagan, USA.
Cancer Biol Ther. 2004 Mar;3(3):305-13. doi: 10.4161/cbt.3.3.697. Epub 2004 Mar 10.
Mammalian cells undergo cell cycle arrest in response to DNA damage due to the existence of multiple checkpoint response mechanisms. One such checkpoint pathway operating at the G(1) phase is frequently lost in cancer cells due to mutation of the p53 tumor suppressor gene. However, cancer cells often arrest at the G(2) phase upon DNA damage, due to activation of another checkpoint pathway that prevents the activation Cdc2 kinase. The kinases, Chk1, Wee1, and Myt1 are key regulators of this G(2) checkpoint, which act directly or indirectly to inhibit Cdc2 activity. Here we show that RNA interference (RNAi)-mediated downregulation of Wee1 kinase abrogated an Adriamycin trade mark -induced G(2) checkpoint in human cervical carcinoma Hela cells that are defective in G(1) checkpoint response. Wee1 downregulation sensitized HeLa cells to Adriamycin trade mark -induced apoptosis. Downregulation of Chk1 kinase in Hela cells also caused a significant amount of cell death in dependent of DNA damage. In contrast, Myt1 downregulation also abrogated Adriamycin trade mark -induced G(2) arrest but did not cause substantial apoptosis. Reduction in Wee1, Chk1, or Myt1 levels did not sensitize normal human mammary epithelial cells (HMEC) cells to Adriamycin trade mark -induced apoptosis unlike the situation in Hela cells. Our study reveals distinct roles for Chk1, Wee1, and Myt1 in G(2) checkpoint regulation. The data reported here support the attractiveness of Wee1 and Chk1 is as molecular targets for abrogating the G(2) DNA damage checkpoint arrest, a situation that may selectively sensitize p53-deficient tumor cells to radiation or chemotherapy treatment.
由于存在多种检查点反应机制,哺乳动物细胞在受到DNA损伤时会经历细胞周期停滞。其中一种在G(1)期起作用的检查点途径,由于p53肿瘤抑制基因的突变,在癌细胞中经常缺失。然而,癌细胞在DNA损伤时通常会停滞在G(2)期,这是由于另一种检查点途径的激活,该途径可阻止Cdc2激酶的激活。激酶Chk1、Wee1和Myt1是这个G(2)检查点的关键调节因子,它们直接或间接作用以抑制Cdc2活性。在这里,我们表明RNA干扰(RNAi)介导的Wee1激酶下调消除了阿霉素商标诱导的G(2)检查点,该检查点在G(1)检查点反应有缺陷的人宫颈癌Hela细胞中存在。Wee1下调使Hela细胞对阿霉素商标诱导的凋亡敏感。Hela细胞中Chk1激酶的下调也导致了大量与DNA损伤无关的细胞死亡。相比之下,Myt1下调也消除了阿霉素商标诱导的G(2)停滞,但没有引起大量凋亡。与Hela细胞的情况不同,Wee1、Chk1或Myt1水平的降低并没有使正常人乳腺上皮细胞(HMEC)对阿霉素商标诱导的凋亡敏感。我们的研究揭示了Chk1、Wee1和Myt1在G(2)检查点调节中的不同作用。这里报道的数据支持将Wee1和Chk1作为消除G(2) DNA损伤检查点停滞的分子靶点的吸引力,这种情况可能会选择性地使p53缺陷的肿瘤细胞对放疗或化疗敏感。